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Development of a Vaccine Against 
Clostridium difficile Infection (CDI):  
Design, Purification, and Biological 




Merck Research Laboratories, Vaccine Basic Research, 
West Point, PA, USA
Clostridium difficile Infection (CDI) 
• Clostridium difficile infection (CDI) is a leading cause of nosocomial 
diarrhea
• CDI can lead to colitis, toxic megacolon, systemic inflammatory 
response syndrome, and death
• 500,000 cases/year in the US 
2
J Med Microbiol. 2011 Aug;60(Pt 8):1070-9.
Nat Rev Microbiol. 2009 Jul;7(7):526-36.
Healthcare Cost and Utilization Project (HCUP) Statistical Briefs Statistical Brief #124, May 2012.  
Clostridium Difficile Infections (CDI) 2009
3
•Substantial morbidity among patients:
•Elderly (age >65 years)
•Immunocompromised
•Undergoing prolonged hospitalization
•Receiving broad-spectrum antibiotics and/or proton 
pump inhibitors
Healthcare Cost and Utilization Project (HCUP) Statistical Briefs Statistical Brief #124, 
May 2012.  
C. difficile Virulence Factors
•Clostridium difficile is an anaerobic spore-forming gram-positive 
bacterium
•The main virulence factors are two clostridial toxins: TcdA and 
4
TcdB
•Asymptomatic carriers of C. difficile have significantly higher serum 
anti-toxin IgG levels as compared with patients who develop primary 
or recurrent CDI (J Med Microbiol. 2011 Aug;60(Pt 8):1070-9) 
Monoclonal Antibodies against TcdA and TcdB 



























• Treatment with monoclonal antibodies CDA1 and CDB1 reduces the rate of disease 
recurrence following SoC treatment (metronidazole or vancomycin)























0 10 20 30 40 50 60 70 80 90
0
P<0.001 Antibody
Domain Structure of C. difficile TcdA and TcdB
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• TcdA and TcdB are large (~300 kDa) proteins composed of N-terminal enzymatic 
domain (ED), glucosyl transferase,  the middle region translocation domain (TD) and C-
terminal, highly repetitive carbohydrate binding domain (CROPS).   
• Native, formalin inactivated Toxoid A/B vaccine is safe and immunogenic, currently in 
Phase II (Sanofi-Aventis)  
• Recombinant CROPS region, chimeric antigens, and DNA vaccines induced 
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1. Which CROPS 
segments induce 
protective antibodies?
Objectives of fragmentation study:  












2. Does TD play a role in a 
development of 
protective immunity? 
3. Does ED contain additional 
neutralizing epitopes?

















TransCROPS B 207 39





• All antigens were purified in the two-step process using Ni-affinity column followed by 
anion exchange chromatography
• Highly purified antigens were obtained (SDS/PAGE) with purification yields 0.5-2 g/L for 


































ED B 63.9 505
* Assuming 20% biomass, after two-step purificaiton
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Toxoid 181,019ED TD CROPS
270 kDa
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Antibody titer
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• Antibody titer was measured in plates coated with native TcdB, incubated with dilutions 
of sera, and detected with secondary antibody 












of Toxin B Antisera
A




Neutralizing Activity of Antisera From 
Hamsters Immunized with TcdB Fragments







• Native TcdB was incubated with tested antiserum for 1 hour and then added to IMR90 
fibroblasts grown in 96-well microtiter plates. The extent of neutralization was assessed 
visually after 24-hour incubation  
• Antisera collected from hamsters immunized with recombinant TcdB fragments 




C. difficile Challenge in Syrian Hamsters –
Experimental Outline
• Immunization phase
Day 0 Day 21 Day 42 Day 63 Day 77
Cleocin 30 mg/kg C. difficile spore 
challenge
Day -5 (Day 79)
Peak death time 
for naïve hamster
42-80 Hr Day 14Day 0
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• Disruption & colonization phase
− “Opening of a colonization window” that allows C. difficile to germinate and 
establish an infection
− Requires antibiotic disruption of the gut microbiota
• Pathological phase
− Colitis, typhilitis, wet tail
− Ultimately death






Toxoid A / Toxoid B
Toxoid A / [ED + TransCROPS B]
Toxoid A / [ED + B0]
Toxoid A/ [ED + B1]














• Hamsters (n=10) immunized with a combination of native Toxoid A and recombinant   
fragments of TcdB were challenged with C. difficile spores  
• Kaplan-Meier analysis demonstrated prolonged survival of hamsters immunized with 
recombinant antigens as compared with adjuvant control  

















Protection of  Hamsters in C. difficile






Toxoid A / [Toxoid B]
Toxoid A / [ED + TransCROPS B (+F)]














• Hamsters (n=10) were immunized with a combination of native TcdA and 
ED+TransCROPS TcdB fragments formalin treated ( +F) or untreated (C)
0 100 200 300 400 500
0 adjuvant control













Protection of  Hamsters in C. difficile





Toxoid A / Toxoid B














• Hamsters (n=10) were immunized with a combination of either native or recombinant 
fragments of TcdB and recombinant fragment of TcdA (A1) and challenged with C. 
difficile spores
0 100 200 300 400 500
0
20 A1 / [ED+TransCROPS B]
adjuvant control













Development of Full-Length Recombinant 
mTcdA and mTcdB Vaccine
• Full-length mTcdA (310 kDa) and mTcdB (270 KDa) were expressed 
using recombinant DNA technology
• Several mutations were introduced to reduce toxicity 
(4-5 log reduction achieved)
• Both antigens were purified to homogeneity in a fully scalable 
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process
Biophysical Analysis of Full-Length 









Antigen Source α-helix β-sheet Turns Unordered Tm (°C) kDa
mTcdA Recombinant 23 26 21 30 65 286 (by AUC)
Toxin A C.difficile 21 28 21 30 307 (Predicted)
Toxin A Published* 32 23 22 22 307 (Predicted)
Toxoid A Published* 32 25 19 24 59.8* 307 (Predicted)
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• CD spectra and analytical centrifugation revealed secondary structure and overall size 
comparable to native toxins and in good agreement with published analysis 
• Recombinant mTcdA and mTcdB induced high ELISA titers and neutralizing antibodies  
(not shown)     
mTcdB Recombinant 23 27 20 30 >85 240 (by AUC)
Toxin B C.difficile 21 28 21 29 270 (Predicted)
Toxin B Published* 36 21 18 25 270 (Predicted)
Toxoid B Published* 36 18 18 28 55.8* 270 (Predicted)
*J Pharm Sci. 2008 Oct;97(10):4194-207 (Acambis)







mTcdA / mTcdB (100)
mTcdA / mTcdB   (20)
mTcdA / mTcdB  (4)














• Recombinant TcdA/TcdB vaccine affords protection against C. difficile challenge (n=10)
• At the 100 µg dose (50 µg each) the level of protection is equivalent to benchmark toxoid 
vaccine
• Vaccine is also effective at 5-fold and 25-fold lower doses  

















• Fragment-based vaccine consisting of the recombinant CROPS 
fragments of Toxin A and B induced high ELISA titers, neutralizing 
antibodies, and good protection against C. difficile challenge.  Larger 
fragments were performing considerably better than small fragments 
of the CROPS region.
• Full-length recombinant mTcdA and mTcdB vaccine induced 
neutralizing antibodies and induced long-lasting protection equivalent 
18
to benchmark toxoid vaccine.
• The final vaccine image including formulation, stability, and dosing is 
under development.
C. difficile Vaccine Team

















































































Lisa Plitnick (Safety Assessment)
Beth Arnold (Clinical Assays)






Cytotoxic Effects of C. difficile Toxins
21
Barth et al, JBC 276(2001):10670-10676
Gieseman et al, JBC 281(2006):10808-10815
Rupnik et al, Microbiology 151(2005):199-208
Pfeifer et al, JBC 278(2003):44535-44541
Abstract
Clostridium difficile is the major cause of antibiotic-associated diarrhea and pseudomembranous colitis, a 
disease associated with significant morbidity and mortality.  The disease is mostly of nosocomial origin, with 
elder patients undergoing anti-microbial therapy being particularly at risk.   A new, hypervirulent strain of C. 
difficile called NAP1 (027) has been implicated in outbreaks associated with increased morbidity and mortality 
since the early 2000s.  This epidemic strain is responsible for increased incidence of C. difficile-associated 
diarrhea related not only to antibiotic exposure, but infection is also associated with GI surgery, prolonged 
hospitalization, and immune-compromising conditions.  C. difficile produces 2 large toxins: Toxin A and Toxin B. 
These 2 toxins act synergistically to damage and impair the colonic epithelium and are primarily responsible for 
the pathogenesis associated with C. difficile infection (CDI).  Testing the feasibility of toxin-based vaccination 
against C. difficile is being investigated.  A native Toxoid A- and B-based vaccine was reported to be safe and 
immunogenic in healthy volunteers.  
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We generated a toolbox of E. coli expressed Toxin B fragments covering the entire molecule and 
systematically explored these fragments as components of an experimental vaccine.  We observed a robust 
immune response in hamsters vaccinated with the recombinant toxin fragments.  The antiserum obtained from 
immunized hamsters was shown to neutralize cytotoxic effects of Toxin B in vitro (in cell-based neutralization 
assay).   Hamsters immunized with the combination of full-length Toxoid A and fragments of Toxin B were 
protected against lethal challenge with C. difficile spores. 
We also evaluated that recombinant full-length mTcdA and mTcdB vaccine and demonstrated excellent 
performance in a hamster challenge model, equivalent to benchmark toxoid vaccine. 
The use of recombinant C. difficile toxins could afford improved protection, vaccine thermal stability, and 
facilitate manufacturability of the vaccine. The additional studies, including thermal stability, formulation, safety, 
and dosing, will be needed to establish the final vaccine image.  














A. Monoclonal antiTcdB (Novus) B. Polyclonal antiTcdB/TcdA
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• Recombinant Toxin B fragments were separated on SDS/PAGE, transferred onto 
nitrocellulose, and probed with monoclonal antobody (5A8-E11) developed against full-
length native Toxin B (Novus Biologicals) (A) or polyclonal antisera from rhesus 





























































C. difficile Infection Prevention: 
Biotherapeutics, Immunologics, and Vaccines
24
Discov Med. 2012 Jan;13(68):75-83.
Gerding DN
Points of Treatment of CDI
25
Discov Med. 2012 Jan;13(68):75-83.
Gerding DN
Sequence Similarity Between TcdA and TcdB
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C. difficile Infection 
• 500,000 hospitalizations in US due to CDI – up to 5% mortality
• Anaerobic spore-forming gram-positive bacillus 
• Causes C. difficile-associated infection (CDI or CDAD)
• Damage to gut lining → diarrhea → pseudomembranous colitis → toxic 
megacolon → sepsis → death
• Main mode of transmission is fecal-oral in hospital setting
27
2011  symptomsbook.com


















(Coomassie Blue) Western Blotting (anti6His)
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• Synthetic genes encoding TcdB fragments were cloned into pET30a vector, expressed 
in (BL21/DE3) E. coli, and purified by two-step chromatography using Ni-affinity 
















































































TransCROPS B 545-2367 207 1832 4.37 8 77 39
TMD B 1129-2367 142 1248 4.3 4 ~50 50
B0 1786-2367 68 592 4.11 1 95 822
B1 1836-2367 62.4 542 4.13 1 99.3 582
29
B2 1836-2101 31.6 275 4.4 0 99.3 1836
B3 1949-2275 39.1 336 4.29 1 99.6 686
B4 2102-2367 32 276 4.07 1 99.6 800
ED B 63.9 559 4.85 1 91 505
* Assuming 20% biomass, after two-step purification
